ABEO (Abeona Therapeutics) 6-Month Price Index: 1.16 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABEO Abeona Therapeutics Inc ABEO
30 GF Score
Price $5.98
! 5 Warning Signs
View Full Analysis

What is Abeona Therapeutics 6-Month Price Index?

Abeona Therapeutics ABEO -0.58% 30 6-Month Price Index is 1.16 as of Aug. 27, 2026. GuruFocus rates ABEO with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-27), Abeona Therapeutics's 6-Month Price Index is 1.16.

Abeona Therapeutics  (NAS:ABEO) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Abeona Therapeutics 6-Month Price Index Related Terms

ABEO vs RCKT, UPB, PALI: 6-Month Price Index Comparison

For the Biotechnology subindustry, Abeona Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABEO
30GF Score
Abeona Therapeutics Inc ABEO
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics  (NAS:ABEO) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.16 mean?
Abeona Therapeutics (ABEO) has a 6-Month Price Index of 1.16 as of Aug. 27, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' 6-Month Price Index too high?
Abeona Therapeutics' current 6-Month Price Index is 1.16. Overall, Abeona Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' 6-Month Price Index compare to RCKT and UPB?
Abeona Therapeutics' 6-Month Price Index of 1.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current 6-Month Price Index is 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current 6-Month Price Index of 1.16. The current 6-Month Price Index is 1.16. Abeona Therapeutics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current 6-Month Price Index is 1.16 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abeona Therapeutics Business Description

Other Exchanges 0H7R:UKPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
30GF Score

Get the complete analysis for ABEO

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.98
Price